Ovid Therapeutics Inc. (OVID)

3.0600 -0.0100 (-0.33%) 收市：04:00PM EDT

Ovid Therapeutics Inc.

41 Ninth Avenue
14th Floor
New York, NY 10001
United States
646 661 7661
https://www.ovidrx.com

版塊: Healthcare
行業: Biotechnology
全職員工: 40

高階主管

名稱	頭銜	支付	行使價	出生年份
Dr. Jeremy Max Levin Ba Zoology, Dphil, Mb Bchir	President, CEO & Chairman	1.03M	無	1953
Mr. Jeffrey A. Rona	Chief Business and Financial Officer	761.24k	無	1968
Mr. Thomas Michael Perone J.D., M.B.A.	General Counsel, Chief Compliance Officer & Corporate Secretary	745.71k	無	1965
Mr. Jason Tardio M.B.A.	Chief Operating Officer	652.84k	無	1977
Mr. Simon D. Kelner	Chief Human Resources Officer	無	無	1974
Dr. Dirk Haasner	Senior Vice President of Global Manufacturing & CMC QA	416.95k	無	1965
Dr. Todd F. Baumgartner M.D., M.P.H.	Senior Vice President of Regulatory Affairs	無	無	無
Dr. Julia Tsai Ph.D.	Senior Vice President of Clinical Development	無	無	1975
Ms. Meg Alexander	Chief Strategy Officer	無	無	無
Dr. Manoj Malhotra M.D.	Chief Medical Officer	無	無	無

截止 2023年12月31日為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 USD。

描述

Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing soticlestat, a novel cholesterol 24 hydroxylase inhibitor, which is in Phase 3 clinical trials for the potential treatment of patients with resistant epilepsies; OV329, a GABA aminotransferase inhibitor which is in Phase 1 clinical trials for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies. It also develops OV815, that focuses on the mutations associated with KIF1A-associated neurological disorder (KAND); OV888 (GV101), a highly selective rock2 inhibitor which is in Phase 1 double-blind multiple-ascending dose trial; OV825, has advanced to potential candidate lead identification for the rare neurodevelopmental condition HNRNPH2 (Bain Syndrome); and OV882, a short hairpin RNA gene therapy for the treatment of Angelman syndrome. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Graviton, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.

公司管治

截至 2024年5月1日 止，Ovid Therapeutics Inc. 的 ISS 管治質素評分為 8。 Pillar 分數正在審核中：8；董事會：8；股東權利：7；現金賠償：8。

企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。